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Abstract 
RAR-related orphan receptor t (ROR-t) directs differentiation of pro-inflammatory T helper 17 (TH17) 
cells and is a potential therapeutic target in chronic autoimmune and inflammatory diseases
1-3
.  However, 
ROR-t-dependent group 3 innate lymphoid cells (ILC3s) provide essential immunity and tissue protection 
in the intestine
4-11
, suggesting that targeting ROR-t could also result in impaired host defense to infection 
or enhanced tissue damage.  Here, we demonstrate that transient chemical inhibition of ROR-t in mice 
selectively reduces cytokine production from TH17 cells but not ILC3s in the context of intestinal infection 
with Citrobacter rodentium, resulting in preserved innate immunity.  Transient genetic deletion of ROR-t in 
mature ILC3s also did not impair cytokine responses in the steady state or during infection.  Finally, 
pharmacologic inhibition of ROR-t provided therapeutic benefit in mouse models of intestinal 
inflammation, and reduced the frequencies of TH17 cells but not ILC3s isolated from primary intestinal 
samples of individuals with inflammatory bowel disease (IBD).  Collectively, these results reveal differential 
requirements for ROR-t in the maintenance of TH17 cell versus ILC3 responses, and suggest that 
transient inhibition of ROR-t is a safe and effective therapeutic approach during intestinal inflammation.
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While therapeutic targeting of the TH17 cell pathway is effective in several autoimmune diseases
12-14
, in 
Crohn’s disease, blockade of IL-17A is ineffective and in some cases was associated with worsened 
disease or increased opportunistic infections
15-17
.  This is consistent with mouse models demonstrating 
protective functions for IL-17A and the often co-expressed cytokine IL-22 in the intestine
18-23
, which is in 
part mediated by ROR-t
+
 ILC3
4-11
.  Small-molecular weight inhibitors of ROR-t are an alternative 
therapeutic approach, with several identified and found to exhibit efficacy in models of autoimmunity
24-28
.  
However, the effect of targeting ROR-t
 
in intestinal immune cells remains unexplored. 
To investigate the impact of ROR-t inhibitors in the intestine, C57BL/6 mice were infected with the 
enteric pathogen Citrobacter rodentium, which elicits ROR-t
+
 TH17 cell and ILC3 responses
6,7,29,30
, and 
treated with a vehicle control or GSK805, a orally-available inhibitor of ROR-t-mediated transcription
24
.  
Relative to vehicle control, oral GSK805 treatment reduced the frequency and total number of IL-17A- and 
IL-22-producing TH17 cells, but not IFN-
+
 TH1 cells, in the colon lamina propria (cLP) and mesenteric 
lymph node (mLN; Fig. 1a, d and e).  In contrast, GSK805 treatment did not alter the percentage or total 
numbers of IL-17A- or IL-22-producing ILC3 in the colon or mLN (Fig. 1b, c and f).  IL-22 production from 
ILC3s and T cells mediates protective immunity to C. rodentium at early versus late stages of infection, 
respectively
6,7,29
.  Consistent with this, GSK805-treated mice had a comparable burden of C. rodentium 
early during infection, but increased levels at later stages as compared to control treated mice 
(Supplementary Fig. 1a).  Preserved innate immunity allowed for 75% of mice to survive at day 20 post 
infection, in contrast to anti-IL-23 monoclonal antibody administration which resulted in 100% mortality 
(Fig. 1g), due to inhibition of ILC3 and TH17 cell responses
7,23,30
.  Colon length was increased (Fig. 1h) 
and histologic signs of inflammation and tissue damage were reduced (Fig. 1i) in GSK805-treated mice 
relative to controls.  In response to a systemic infection with the opportunistic pathogen Candida albicans, 
vehicle control and GSK805-treated mice had comparable IL-17A
+
 ILC3 responses in the spleen, fungal 
burdens, and a lack of inflammation in the kidney, as opposed to Il17a
–/–
 mice which exhibited significantly 
increased fungal burdens and kidney inflammation (*P < 0.05, Supplementary Fig. 1b–d).   
To further define the requirements for ROR-t in the maintenance of ILC3 responses, we 
generated mice where Rorc can be temporally deleted in mature ILC3.  This was accomplished by 
crossing Rorc
floxed
 mice and Id2
creERT2
 mice, which targets cre recombinase activity to ILCs following 
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tamoxifen administration (Supplementary Fig. 2a), to generate Id2
iΔROR-γt
 mice.  After 2 weeks of 
tamoxifen administration, comparable frequencies of total ILCs (Lineage
–
(Lin
–
)CD127
+
) were observed in 
the mLN of control and Id2
iΔROR-γt
 mice, with efficient deletion of ROR-t protein (Fig. 2a).  Despite a loss of 
ROR-t, analyses of the total ILCs revealed comparable frequencies of cells with an ILC3-like phenotype, 
including those expressing CCR6, CD4 and MHCII in the mLN of control and Id2
iΔROR-γt
 mice (Fig. 2b, c).  
Futher, microarray analyses of sort purified CCR6
+
 ILCs (gated as Lin
–
CD127
+
CCR6
+
) revealed a 
decrease in Rorc transcripts from tamoxifen administered Id2
iΔROR-γt
 mice relative to Rorc
floxed
 mice, but 
sustained expression of other genes associated with ILC3 function (Fig. 2d).  To determine how long 
ILC3-like cells could persist in the absence of Rorc, 6 week old Id2
iΔROR-γt
 mice were continuously 
administered tamoxifen for 12 weeks.  At this time point, cells with an ILC3-like phenotype could be 
observed in the mLN, with modest changes in absolute cell numbers and surface markers 
(Supplementary Fig. 3).  In contrast, an ILC3-like population was not maintained in the small intestine, 
but rather an increase in the numbers of Lin
–
CD127
+
NKp46
+
 ILC1-like cells was evident (Supplementary 
Fig. 4).  These results suggest that loss of ROR-t may cause an expansion of ex-ILC3 or ILC1 in the 
small intestine
31-33
, or a loss of pro-inflammatory ILC3
34,35
.  Consistent with a loss in pro-inflammatory 
ILC3, a decrease in IFN-
+
 ILCs was observed in the small intestine, while no change was observed in the 
mLN (Supplementary Fig. 4).   Despite changes in the intestine, comparable frequencies and numbers of 
ILCs lacking detectable ROR-t expression but able to produce both IL-17A and IL-22 were maintained in 
the mLN following 12 weeks of continuous tamoxifen administration (Supplementary Fig. 4).  
Consistent with a preservation of ILC3 function, tamoxifen-administered Rorc
floxed
 control and 
Id2
iΔROR-γt
 mice exhibited comparable IL-17A
+
 ILC3 responses in the spleen, CFU and a lack of 
inflammation in the kidney following infection with C. albicans (in contrast to Il17a
–/–
 mice, Supplementary 
Fig. 2b, c).  Furthermore, Rorc
floxed
 and Id2
iΔROR-γt 
mice exhibited comparable IL-22
+
 ILC3 responses in the 
mLN following C. rodentium infection (Fig. 2e).  To compare these results to transient genetic deletion of 
ROR-t in CD4
+
 T cells, Rorc
floxed
 mice were crossed to CD4
creERT2
 mice, to generate CD4
iΔROR-γt
 mice.  IL-
17A production was reduced in CD4
+
 T cells in the mLN of tamoxifen-administered and Citrobacter 
rodentium infected CD4
iΔROR-γt
 mice relative to littermate controls (Fig. 2f), demonstrating differential 
requirements for ROR-t in ILC3 versus TH17 cells.  Further, 75% of Id2
iΔROR-γt
 mice survived at day 20 
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post infection with C. rodentium, in comparison to mice with a genomic deletion in ROR-t (Rorc
-–/–
 mice) 
and thus impaired ILC3 and TH17 development, which exhibited 100% mortality (Fig. 2g).  CD4
iΔROR-γt
 
mice were partially susceptible at later stages post-infection (Fig 2g), yet exhibited increased colon length 
(Fig. 2h) and reduced histologic signs of intestinal inflammation (Fig. 2i) relative to control and Id2
iΔROR-γt
 
mice, suggesting that while TH17 cells are important for immunity at late stages of infection, they also are 
primary mediators of intestinal damage and inflammation.  
Previous studies reported a low turnover rate of ILC3
36
, and pulse-chase experiments with 
tamoxifen administration in Id2
iΔROR-γt
 mice revealed differing half-lives of ILC3 in the mLN and intestine 
(Supplementary Fig. 5).  Further, in all tissues assessed, the markers of proliferation were higher in TH17 
cells than ILC3 at steady state (Supplementary Fig. 6).  However, this did not account for the differential 
requirements of sustained ROR-t expression, as treatment of mice with IL-2/anti-IL-2 complexes induced 
ILC3 proliferation (Supplementary Fig. 7) and equally expanded a population of the RORt
–
 ILC3 in the 
mLN of tamoxifen treated Id2
iΔROR-γt
 mice that produced comparable levels of IL-17A and IL-22 relative to 
RORt
+
 ILC3 in control mice (Supplementary Fig. 8).   
To experimentally address whether chemical inhibition of ROR-t can provide therapeutic benefit 
in the context of intestinal inflammation, Il10
–/–
 mice were aged to 10 weeks (a time point at which 
spontaneous colonic inflammation is observed), and orally administered either vehicle control or GSK805 
at a dose 10 mg/kg/day for two weeks.  GSK805 administration selectively reduced the frequency of IL-
17A
+
 TH17 cells in the colonic tissues, while no effect on the frequency of IL-17A
+
 ILC3 was observed (Fig. 
3a).  Furthermore, GSK805 treatment reduced elevated amounts of fecal lipocalin-2 (Fig. 3b), prevented 
shortening of the colon (Fig. 3c) and reduced histologic signs of inflammation in the colon (Fig. 3d) of 
Il10
–/–
 mice relative to controls.  In a second model of intestinal inflammation, CBir1 transgenic CD4
+
 T 
cells, which recognize an immunodominant and commensal bacteria-derived antigen in Crohn’s disease
37
, 
were transferred to Rag1
–/–
 mice.  At two weeks post transfer, intestinal inflammation was observed and 
then mice were orally administered either vehicle control or GSK805 at a dose 10 mg/kg/day for two 
weeks.  GSK805 treatment significantly reduced the frequency of colonic CBir1-specific TH17 cells, but not 
IL-17A
+
 ILC3 (**P < 0.01, Fig. 3e).  Further, GSK805 treatment reduced fecal lipcalin-2, colonic shortening 
and histologic signs of inflammation in the colon of Rag1
–/–
 mice receiving a CBir1 T cell transfer, relative 
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to control mice (Fig. 3f–h).  Together, these results demonstrate that transient inhibition of ROR-t 
provides therapeutic benefit in the context of two mouse models of intestinal inflammation. 
To interrogate how transient inhibition of ROR-t modulates human TH17 cell and ILC3 responses, 
colonic resection tissues from pediatric individuals with Crohn’s disease were digested and single cell 
suspensions were cultured in vitro for 12 hours in the presence of DMSO control or GSK805.  ILC3s were 
identified by gating on Lin
–
 cells and examining for CD127
+
 populations (Fig. 4a) followed by co-
expression of NKp44 and c-kit.  Incubation with GSK805 relative to DMSO control did not alter ILC3 
frequencies (Fig. 4b), production of IL-22 (Fig. 4c), or production of the pro-inflammatory cytokine TNF 
(Fig. 4d).   In contrast, in vitro culture with GSK805 resulted in a decrease in the frequency of CD4
+
 T cells 
that produce IL-17A (Fig. 4e) and IL-22 (Fig. 4f) relative to DMSO.  The decrease in IL-17A
+
 and IL-22
+
 
TH17 cells following culture in the presence of GSK805 was observed in cell suspensions from 8 out of 10 
pediatric individuals with Crohn’s disease (Fig. 4g), did not influence IFN-
+
 T cells (Fig. 4h), and resulted 
in comparable or increased frequencies of IL-17A
+
 and IL-22
+
 ILC3 (Fig. 4i).  Similar data were also 
obtained when another ROR-t inhibitor, Digoxin
25
, was utilized in vitro (Supplementary Fig. 9). 
Collectively, these results demonstrate that similar to mice, transient in vitro inhibition of ROR-t in cells 
isolated from individuals with IBD selectively limits TH17 cells, with limited influence on ILC3s.   
 Subsets of ILCs and CD4
+
 T helper cells exhibit remarkably similar transcriptional profiles and 
effector cytokine responses, yet can promote differential functions in the context of immunity, inflammation 
and tissue repair
1-3,11,38
.  Therefore, therapeutically targeting conserved pathways in the context of chronic 
inflammatory diseases has the potential to influence both arms of the immune system, and in addition to 
limiting a pathologic response, could inappropriately target beneficial responses that mediate protective 
immunity or tissue repair.  This may account for off-target consequences of biologic therapies in patients 
with IBD that broadly inhibit cytokine-cytokine receptor interactions, such as the anti-IL-17 clinical trials 
that resulted in increased infections or worse disease
15-17,39
.  Here, we uncover an unexpected cellular 
mechanism by which transient inhibition of the transcription factor ROR-t allows for selective targeting of 
adaptive TH17 cells without influencing protective ILC3 responses in both mice and in vitro cultures with 
human tissues samples.  These data provoke a challenge to our understanding of the modular effects of 
lineage-specifying transcription factors in the maintenance and function of innate versus adaptive 
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lymphocytes, and identify ROR-t inhibition as an attractive future therapeutic approach to treat IBD and 
other chronic inflammatory diseases. 
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Figure Legends 
 
Figure 1. Transient chemical inhibition of ROR-t selectively reduces TH17 responses but not ILC3s 
during infection. (a–i) C57BL/6 mice were infected with C. rodentium and treated daily with vehicle 
control or GSK805 (10 mg/kg) starting on day –1 and continued for the duration of the experiment (a) 
Frequency of IL-17A-producing TH17 cells and (b) IL-17A- or (c) IL-22-producing ILC3 at day 10 post 
infection.  (d) Total numbers of IL-17A
+
 and IL-22
+
 TH17 cells, (e) IFN-
+
 T cells and (f) IL-17A
+
 and IL-22
+
 
ILC3 in the colon at day 10 post infection. (g) Survival curve of infected mice. (h) Colon length and (i) 
Hematoxylin and eosin stained histologic sections of the distal colon at day 10 post infection, 
representative of n = 5.  Scale bar, 200 μm.  All data are representative of five individual mice (n = 5) and 
was replicated in two independent experiments.  Data shown are mean ± SEM (error bars). Statistics 
compare treatment versus control groups using Student’s t test. *P < 0.05,  **P < 0.01, ***P < 0.001.  
 
Figure 2. Transient genetic deletion of ROR-t impairs TH17 cells but not ILC3s during homeostasis 
and intestinal infection. (ag) Analyses of ILC3s in Rorc
floxed
 control and Id2
iΔROR-γt
 mice following daily 
treatment with tamoxifen for two weeks.  (a) Gating for ILCs and subsequent analysis for ROR-t.  Lin
–
CD127
+
 cells from the mLN were analyzed for (b) CCR6 and (c) CD4 protein, as well as sequential gating 
for MHCII protein.  (d) Relative expression of ILC3-associated genes from mLN sort purified CCR6
+
 ILCs 
was assessed by genome-wide microarrays. (eh) Mice were infected with C. rodentium and treated daily 
with tamoxifen starting on day –1.  (e) Identification of IL-22-producing ILC3 and (f) IL-17-producing TH17 
cells at day 10 post infection.  (i) Survival curve of infected mice. (g) Colon length and (h) Hematoxylin 
and eosin stained histologic sections of the distal colon at day 10 post infection, representative of n = 5.  
Scale bar, 200 μm. All data are representative of five individual mice (n = 5) and was replicated in two 
independent experiments.  Data shown are mean ± SEM (error bars).  Statistics compare treatment 
versus control groups using Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001 
 
Figure 3. Transient inhibition of ROR-t selectively limits TH17 cell responses and reduces 
intestinal inflammation.  (ad) Ten-week-old Il10
–/–
 mice were treated with vehicle control or GSK805 
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(10 mg/kg) for two weeks. (a) Frequency of IL-17A-producing TH17 cells (red) or ILC3 (blue). Amount of 
fecal lipocalin-2 (b), colon length (c), and Hematoxylin and eosin stained histologic sections of the distal 
colon (d).  Scale bar, 200 μm, representative of n = 5.  (eh) Adoptive transfer of CBir1 TCR transgenic T 
cells into Rag1
–/–
 mice, followed 2-3 weeks later by daily treatment with either vehicle control or GSK805 
(10 mg/kg) for 2 weeks.  (e) Analyses of IL-17A-producing TH17 cells (top) or ILC3 (bottom), (f) amount of 
fecal lipocalin-2, (g) colon length, and (h) Hematoxylin and eosin stained histologic sections of the distal 
colon.  Scale bar, 200 μm, representative of n = 5.  All data are representative of five individual mice (n = 
5) and was replicated in two independent experiments.  Data shown are mean ± SEM (error bars). 
Statistics compare treatment versus control groups using Student’s t test. *P < 0.05, **P < 0.01, ***P < 
0.001 
 
Figure 4. Transient inhibition of ROR-t selectively reduces TH17 cells in intestinal tissue from 
pediatric individuals with Crohn’s disease.  (a–i) Intestinal resection tissue from pediatric individuals 
with Crohn’s disease was cultured with DMSO control or GSK805 (0.5 μM) for 12 hours. (a) Identification 
of Lin
–
IL-7Rα
+
 ILCs. (b) Percentage of NKp44
+
c-kit
+
 ILC3s.  (c) Production of IL-22 and (d) TNF by gated 
c-kit
+
 ILC3s.  (e) Expression of IL-17A and (f) IL-22 by CD3
+
 TH17 cells.  (g) Fold change in the 
percentage of IL-17A
+
 or IL-22
+
 TH17 cells, (h) IFN-
+
 TH1 cells and (i) IL-17A
+
 or IL-22
+ 
ILC3 following 
culture with GSK805 relative to DMSO.  All data are representative or shown for n = 10 samples from 
pediatric individuals with Crohn’s disease. 
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Online methods 
Mice 
C57BL/6, CD4
creERT2 
(ref. 
40
),
 
Id2
creERT2 
(ref. 
41
), Rorc
–/–
, Il10
–/–
, ROSA
mT/mG
, Rag1
–/–
, and Rorc
floxed
 (ref. 24) 
mice were originally obtained from the Jackson Laboratory (Bar Harbor, ME) and bred and maintained at 
Weill Cornell Medical College, (New York, NY, USA) or the University of Birmingham (Birmingham, UK).  
CBir1 mice and Il17a
–/–
 mice were previously described
37,42
.   Mice used were a mix of male and female 
animals, aged 6-10 weeks at the start of the experiment.  For experiments at the University of 
Birmingham, animals were used in accordance with Home Office guidelines at the University of 
Birmingham.  For experiments performed at Weill Cornell, all protocols were approved by the Weill Cornell 
Institutional Animal Care and Use Committee (IACUC), and all experiments were performed according to 
the guidelines of the Weill Cornell IACUC.  To generate Id2
iΔROR-γt
 and CD4
iΔROR-γt
 mice, Id2
creERT2
 and 
CD4
creERT2
 mice were crossed to Rorc
floxed 
mice respectively.  Where noted, experimental and control mice 
were maintained on Tamoxifen-containing diet (TAM400, Harlan Laboratories) for at least 10-14 days prior 
to analysis or infection, or were gavaged daily with 10 mg/kg of tamoxifen in corn oil (Sigma).  GSK805 
(C₂ ₃ H₁ ₈ Cl₂ F₃ NO₄ S) was previously identified by a Fluorescence Resonance Energy Transfer 
(FRET) assay that examined for inhibition of the ROR-t ligand-binding domain and cofactor peptide SRC1 
and compared to other nuclear receptors
24
.  Inhibition of ROR- was not tested.  Efficacy and potency was 
previously demonstrated, and RNAseq data revealed comparable transcriptional changes to that observed 
in Rorc gene deletion
24
.  In this study, GSK805 was provided from EMD Milipore (53136) at a purity ≥ 95% 
by HPLC.  Mice received 10 mg/kg/day of GSK805 dissolved in DMSO and provided by oral gavage in 
corn oil, or DMSO alone in corn oil as a vehicle control.  For BrdU incorporation, mice were given 1.5 mg 
BrdU i.p. and analyzed after 24 hours. Mice were injected i.p. for 3 consecutive days with IL-2/anti-IL2 
complexes generated by mixing recombinant protein and antibody for 30 minutes at 37 °C prior to 
injection.  Per injection, each mouse received 1 µg IL-2 (Peprotech) and 5 µg anti-IL-2 monoclonal 
antibody (clone JES6-1A12, eBioscience), and control mice received PBS.  No animals were excluded 
from the analyses.   
   
Citrobacter rodentium infection  
Citrobacter rodentium (formerly Citrobacter freundii, biotype 4280) strain DBS100 was prepared by 
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selecting a single colony and culturing in LB broth overnight as previously described
7
.  Mice were 
inoculated with approximately 1 x 10
8
 CFU in 200-250 μL broth via oral gavage.  Quantification of fecal 
CFU was determined by homogenization in sterile PBS and serial dilutions on MacConkey’s agar.   
 
Candida albicans infection  
Candida albicans infections were performed as previously described
43
.  In brief, 10
4
10
5
 CFU of Candida 
albicans strain SC5314 were administered to mice by i.v. injection and analyzed three days later. 
 
Mouse models of intestinal inflammation 
To induce intestinal inflammation, Il10
–/–
 mice were aged to 10 weeks in our animal facilities, followed by 2 
weeks of GSK805 treatment as described above.  The CBir1 T cell transfer model of intestinal 
inflammation was previously described
44
.   In brief, 2 x 10
6
 CD3
+
CD4
+
 T cells were sort purified as from 
spleens of CBir1 transgenic mice and adoptively transferred to Rag1
–/–
 recipients by i.v. injection. This 
protocol induces substantial colonic inflammation at 3 to 4 weeks
44
, at which point mice were then treated 
for 2 weeks with GSK805 as described above. 
 
Flow cytometry 
Lymph nodes were teased using fine forceps and digested for 25 minutes in RPMI containing with 250 
µg/ml Collagenase-Dispase (Roche) and 25 µg/ml DNase I. Digested tissue was then crushed through a 
70 μm nylon mesh.  In some experiments, LNs were only crushed through a 70 μm nylon mesh.  Antibody 
staining was performed at 4 °C for 30 minutes.  Antibodies raised against the following mouse antigens 
were used: B220 (clone RA3-6B2, eBioscience), CCR6 (clone 29-2L17, Biolegend), CD3 (clone 145-
2C11, eBioscience), CD4 (clone GK1.5, eBioscience), CD45.1 (clone A20, eBioscience), CD45.2 (clone 
104, eBioscience), CD5 (clone 53-7.3, eBioscience), CD11b (clone M1/70, eBioscience), CD11c (clone 
N418, eBioscience), GATA-3 (TWAJ, eBioscience), MHCII (clone AF6-120.1, eBioscience), IL-7Rα (clone 
A7R34, eBioscience), IL-17A (clone TC11-18H10.1, eBioscience), IL-22 (clone 1H8PWSR, eBioscience), 
Ki-67 (clone SolA15, eBioscience), NKp46 (clone 29A1.4, eBioscience), ROR-t (clone B2D, eBioscience), 
T-bet (clone eBio4B10, eBioscience).  All antibodies were used at a 1:200 dilution.  The lineage dump 
channel contained antibodies against B220, CD3, CD5, NK1.1, CD11b and CD11c all in one cocktail, or 
 16 
divided into two channels.  Intracellular staining was done using the FoxP3 fixation and permeabilization 
kit (eBioscience) according to manufacturer’s instructions. Incorporation of BrdU was detected using FITC 
BrdU Flow Kit (BD) according to manufacturer’s instructions.  Addition of Spherotech Accucount blank 
particles was used to calculate absolute cell numbers.  Flow cytometry was performed on a Fortessa 
analyzer using FACSDiva6.2 software (BD), with data subsequently analyzed with FlowJo software (Tree 
Star).   For cytokine production, cells were cultured ex vivo in the presence of either mouse recombinant 
IL-1β (14-8012), IL-2 (14-8021), IL-6 (14-8061) and IL-23 (14-8231) at a concentration of 20 ng/mL for 2 
hours (all obtained from eBioscience).  Cells were then stimulated with 50 ng/mL PMA, 750 ng/mL 
Ionomycin and 10 μg/mL Brefeldin A (all obtained from Sigma-Aldrich) for 4 hours. 
 
Microarray analysis 
For microarray analysis,
 
Lin
–
CCR6
+
CD90.2
+
 cells were sorted from the mLN of Rorc
floxed
 or Id2
iΔROR-t mice 
were lysed directly in TRIzol. RNA was isolated, amplified, reverse-transcribed to cDNA and hybridized to 
an Affymetrix GeneChip (Mouse Gene 1.0ST), or obtained via the GEO database and normalized as 
previously described (41).  All data sets were deposited in the GEO database and are available at 
ascension code GSE76201. 
 
Histological sections 
Distal colons were fixed with 4% PFA and embedded in paraffin, and 5 μm sections were cut and stained 
with Hematoxylin and eosin.  Whole kidneys were fixed with 4% PFA and embedded in paraffin, and 5 μm 
sections were cut, stained with Periodic acid–Schiff and counterstained with Hematoxylin. 
 
Human tissue and flow cytometry 
Deidentified intestinal resection tissues from the colon of pediatric individuals with Crohn’s disease were 
obtained from the Children’s Hospital of Philadelphia (CHOP) following an CHOP Institutional Review 
Board (IRB) approved protocol (14-010981) and informed consent of participating individuals.  Tissues 
were processed by first incubating in 1 mM EDTA, 1 mM DTT and 5% FCS (all obtained from Fisher 
Scientific) for 30 minutes at 37 °C with shaking to remove intestinal epithelial cells.  Supernatants were 
then discarded and the remaining tissues were incubated in 0.5 mg/mL collagenase/dispase and 20 
 17 
μg/mL DNase I for 20-30 minutes at 37°C with shaking to obtain the lamina propria fraction.  Any 
remaining tissues were also included following mechanical dissociation and filtering through a 70 μm cell 
strainer.  All cells were then viably cryopreserved at 150 °C in 90% FBS and 10% DMSO for future side-
by-side analyses.  Following thawing, cells were re-stimulated ex vivo with human recombinant IL-1β, IL-2, 
IL-6, IL-7 and IL-23 (20 ng/mL, eBioscience) for 8 hours in the presence of DMSO control, 0.5 µM 
GSK805 (EMD Milipore) or 5 μM digoxin (Sigma-Aldrich).  Cells were then stimulated with 50 ng/mL PMA, 
750 ng/mL Ionomycin and 10 μg/mL Brefeldin A (all obtained from Sigma-Aldrich) for 4 hours.   Cells were 
then stained with antibodies for the following markers: anti-CD3 (clone UCHT1, eBioscience), anti-CD4 
(clone OKT-4, eBioscience), anti-CD5 (clone UCHT2, eBioscience), anti-CD11b (clone M1/7B, 
eBioscience), anti-CD11c (clone 3.9, eBioscience), anti-CD14 (clone 61D3, eBioscience), anti-CD19 
(clone 2H7, eBioscience), anti-CD127 (clone A019D5, Biolegend), anti-FcεR1 (clone AER-37, 
eBioscience), anti-CD117/c-kit (clone 104D2, eBioscience), anti-NKp44 (clone Z231, BC Cytometry).  For 
intracellular staining, cells were fixed and permeabilized using a commercially available kit (eBioscience) 
and staining with anti-IL-17A (clone eBio64DEC17, eBioscience), anti-IL-22 (clone 22URTI, eBioscience) 
or anti-IFN- (clone 4S.B3, eBioscience).  All antibodies were used at a 1:200 dilution.  Lineage cocktails 
are defined in Figure 4 as the x-axis: CD19, CD11b, CD11c, and the y-axis: CD3, CD5, CD14, FcεR1. 
 
Statistics 
Data were analysed using GraphPad Prism (version 5.01). Student‘s t test or Mann-Whitney were used to 
determine significance which was set at P < 0.05.  We did not use statistical methods to predetermine 
sample size, there was no randomization designed in the experiments, and the studies were not blinded.  
Samples sizes were estimated based upon sample availability and previous experimental studies of the 
intestinal immune system
8,9,45,46
.  No exclusion criteria were utilized in these studies. 
 
40. Aghajani, K., Keerthivasan, S., Yu, Y. & Gounari, F. Generation of CD4CreER(T(2)) transgenic mice to 
study development of peripheral CD4-T-cells. Genesis 50, 908-913 (2012). 
41. Rawlins, E.L., Clark, C.P., Xue, Y. & Hogan, B.L. The Id2+ distal tip lung epithelium contains individual 
multipotent embryonic progenitor cells. Development 136, 3741-3745 (2009). 
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42. Nakae, S., Nambu, A., Sudo, K. & Iwakura, Y. Suppression of immune induction of collagen-
induced arthritis in IL-17-deficient mice. J Immunol 171, 6173-6177 (2003). 
43. Bar, E., Whitney, P.G., Moor, K., Reis e Sousa, C. & LeibundGut-Landmann, S. IL-17 regulates 
systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40, 117-127 
(2014). 
44. Feng, T., Wang, L., Schoeb, T.R., Elson, C.O. & Cong, Y. Microbiota innate stimulation is a 
prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med 207, 
1321-1332 (2010). 
45. Sonnenberg, G.F., et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident 
commensal bacteria. Science 336, 1321-1325 (2012). 
46. Mackley, E.C., et al. CCR7-dependent trafficking of RORgamma(+) ILCs creates a unique 
microenvironment within mucosal draining lymph nodes. Nat Commun 6, 5862 (2015). 
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Supplementary Figure 1. Mice treated with GSK805 control early C. rodentium and C. 
albicans infections. (a) Kinetic CFU counts per g/feces in mice treated with vehicle control, 
GSK805 or anti-IL-23p19 monoclonal antibody following C. rodentium infection.  (b–d) C57BL/6 
mice were infected with C. albicans, treated daily with vehicle control or GSK805 (10 mg/kg) 
starting on day 1, and sacrificed on day 3. (b) Frequency of IL-17A producing ILC3. (c) CFU in the 
kidney and (d) Periodic acid-Schiff stained histologic sections of the kidney.  Scale bar, 200 μm.   
All data are representative of five individual mice (n = 5) and was replicated in two independent 
experiments.  Data shown are mean ± SEM (error bars). Statistics compare treatment versus 
control groups using Student’s t test. *P < 0.05, **P < 0.01, ***P < 0.001. 
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Supplementary Figure 2. Id2iΔROR-t mice are protected from infection with C. albicans. (a) Cre 
activity in CD127+ ILCs was assessed using ROSAmT/mG control and Id2creERT2 × ROSAmT/mG mice 
maintained on tamoxifen containing food for 3 weeks, n = 5 ROSAmT/mG control and 6 Id2cre/ERT2 × 
ROSAmT/mG mice. Data pooled from two independent experiments and assessed using Mann-
Whitney two tailed non-parametric test. *P < 0.05, **P < 0.005; bar represents median. (b,c) Mice 
were infected with C. albicans, treated daily with oral tamoxifen starting on day 1, and sacrificed on 
day 3. (b) Identification of IL-17A producing ILC3 and (c) Periodic acid-Schiff stained histologic 
sections of the kidney. Scale bar, 200 μm.   
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Supplementary Figure 3. Phenotypic analysis of ROR-t+ and ROR-t ILC3 populations in 
the mLN following genetic deletion of Rorc for 12 weeks. Rorcfloxed and Id2iΔROR-t mice were 
maintained on tamoxifen for 12 weeks and ILCs isolated from the mLN and characterized. (a) 
Gating strategy to identify ILC3 through exclusion of ILC2 (GATA-3+) and ILC1 (NKp46+).  CD3i, 
CD3 intracellular.  ROR-t+ ILC3 in control Rorcfloxed mice shown in black, ROR-t ILC3 in control 
Id2iΔROR-t mice shown in blue. (b) Overlays of histograms of MHCII, CCR6, CD25, c-kit and CD90 
(Thy1) expression by ROR-t+ ILC3 (black) and ROR-t ILC3 (blue) as identified in (a). Total 
number of ILC and ILC3 (GATA-3NKp46 ILC) (c) and ROR-t+ and ROR-t ILC3 (d), bars show 
median, n = 4 (Rorcfloxed) and 8 (Id2iΔROR-t) mice.  (e) Analysis of MFI of MHCII, CCR6, CD25, c-kit 
and CD90 (Thy1) protein by ROR-t+ (white) and ROR-t (grey) ILC3, mean and SEM shown, n = 4 
(Rorcfloxed) and 6 (Id2iΔROR-t) mice Data pooled from two independent experiments and assessed 
using Mann-Whitney two tailed non-parametric test. *P < 0.05, **P < 0.005; bar represents median 
or SEM in (e).  
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Supplementary Figure 4. Persistence of functional ILC3 in the mLN following genetic 
deletion of Rorc for 12 weeks. Rorcfloxed and Id2iΔROR-t mice were maintained on tamoxifen 
containing food for 12 weeks, cells from the mLN and siLP isolated and then stimulated ex vivo to 
assess cytokine expression. (a) Absolute numbers of IL-17A+, IL-22+, and IFN-+ cells that were 
ROR-t+, ROR-t or total in the small intestine lamina propria (siLP) of Rorcfloxed (n = 4) and 
Id2iΔROR-t (n = 6). (b) Gating strategy to assess non-ILC2 (GATA-3) ILC populations in siLP using 
ROR-t+ and NKp46. ROR-t+ (black) ROR-tNKp46hi (blue) and ROR-tNKp46 (red) cells 
identified and then enumerated (c), bars show median, n = 4 (Rorcfloxed) and n = 6 (Id2iΔROR-t) mice.  
(d) Expression of IL-17A, IL-22 and IFN- versus ROR-t in CD45+CD127+Lin cells from the mLN, 
representative plots shown from 2 independent experiments. (e) Absolute numbers of IL-17A+, IL-
22+, and IFN-+ cells that were ROR-t+, ROR-t or total in mLN of Rorcfloxed (n = 4) and Id2iΔROR-t 
(n = 6).  Data from one of two independent experiments shown. Data assessed using Mann-
Whitney two-tailed non-parametric test. *P < 0.05, **P < 0.005. 
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Supplementary Figure 5. ILC3 half-life differs in the mLN and small intestine. Rorcfloxed and 
Id2iΔROR-t mice were maintained on food containing tamoxifen for 2 weeks, then normal food for a 
further 4 weeks. Cells were prepared from mLN and the small intestine lamina propria (siLP) and 
then stimulated to assess cytokine and ROR-t expression. IL-17A, IL-22 and IFN- protein versus 
ROR-t by CD45+CD127+Lin cells isolated from (a) mLN and (b) siLP, representative plots shown 
from 2 independent experiments. Total numbers of IL-17A+, IL-22+, and IFN-+ in mLN (c) and siLP 
(d) of Rorcfloxed (n = 4) and Id2iΔROR-t  (mLN n = 5, siLP n = 4) mice, data pooled from two 
independent experiments. Data assessed using Mann-Whitney two-tailed non-parametric test. *P < 
0.05; bar represents median.  
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Supplementary Figure 6. TH17 cells proliferate more than ILC3 in the small intestine. ILC3 
and TH17  populations from different tissues were assessed for evidence of proliferation. (a) 
Expression of Ki-67 by ILC3 (CD45+LinCD127+ROR-t+) cells and TH1 (CD45
+CD4+CD3+ROR-t+) 
cells isolated from the small intestine lamina propria (SI)  of C57BL/6 mice, data representative of 4 
mice. (b) Percentage Ki-67+ TH17 and ILC3 in siLP, mLN, inguinal (i) LN and spleen (spln), data 
pooled from two independent experiments (n = 4, 7, 6, 6). (c) Percentage of BrdU+ TH17  CCR6
+ 
and CCR6 ILC3 in siLP, 18 hours after 1.5 mg BrdU injected i.p. Data pooled from two 
experiments, n = 6 C57BL/6 mice. Data assessed using Mann-Whitney two-tailed non-parametric 
test. **P < 0.05, *P < 0.005; bar represents median. 
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Supplementary Figure 7. Treatment with IL-2/anti-IL-2 complexes induces ILC2 and ILC3 
proliferation.  C57BL/6 mice received PBS or IL-2/anti-IL-2 complexes (1 µg IL-2 and 5 µg anti-IL-
2 monoclonal antibody per injection per mouse) i.p. for three consecutive days and the spleen and 
mLN were then analyzed on the following day. (a) Representative plots of Ki-67 expression by ILC3 
and group 2 ILCs (ILC2). Quantitation of ILC3 (b) and ILC2 (c) expressing Ki-67 in spleen and 
mLN. Data (n = 6) pooled from two independent experiments.  Data assessed using Mann-Whitney 
two-tailed non-parametric test. **P < 0.005; bar represents median. 
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Supplementary Figure 8. IL-2/anti-IL-2 complexes drive expansion of functional ILC3s in the 
absence of ROR-t expression. Rorcfloxed and Id2iΔROR-t mice were maintained on tamoxifen for 10 
weeks, given PBS or IL-2/anti-IL-2 complexes i.p. for three consecutive days, and then analyzed 5 
days after the final injection. (a) Representative plots of the gating strategy and expression of IL-
17A, IL-22 and IFN- by ILC from the mLN after stimulation. (b) Quantification of numbers of ROR-
t+, ROR-t and total IL-17A, IL-22 and IFN- expressing ILC. Data (n = 7) pooled from two 
independent experiments. Bars show median. (c) Total numbers of ILC in mLN of control and IL-
2/anti-IL-2 treated mice. Data pooled (n = 810) from 3 independent experiments and assessed 
using Mann-Whitney two-tailed non-parametric test. **P < 0.005.  
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Supplementary Figure 9. Transient inhibition of ROR-t selectively reduces TH17 cells in 
intestinal tissues from pediatric individuals with Crohn’s diseases. (a–i) Intestinal resection 
tissue from pediatric IBD patients was cultured with Digoxin or DMSO control for 12 hours and 
examined for TH17 cell and ILC3 responses. (a) Identification of Lineage
IL-7Rα+ ILCs. (b) 
Percentage of NKp44+c-kit+ ILC3s.  (c) Production of IL-22 and (d) IFN- by gated c-kit+ ILC3s. (e) 
Expression of IL-17A and (f) IL-22 by Lineage+ TH17 cells (red) and Lineage
 ILC3s (blue). (g) Fold 
change in the percentage of IL-17A+ or IL-22+ TH17 cells, (h) IFN-
+ TH1 cells and (i) IL-17A
+ or IL-
22+ ILC3.  All data are representative or shown for n = 10 pediatric individuals with Crohn’s disease. 
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